Boston, MA 02/11/2014 (wallstreetpr) – Oracle Corporation (NYSE:ORCL) is aggressively pushing into software defined network (SDN) where it seeks to topple network hardware providers like Cisco Systems Inc (NASDAQ:CSCO). Last month the company acquired Corente, a firm which manages and proves applications and services over a wide area regardless of IP network. And the latest move by ORCL is a deal with Pluribus which once again goes a long way to heap coal on the head of networking giant Cisco. This latest agreement, according to Oracle Corporation (NYSE:ORCL), would allow customers to manage OpenSolaris 11 node by using OpenStack Nova plugin. Basically, this step takes ORCL’s move to be a formidable force in the cloud network solution a notch higher.
Delta Air Lines, Inc. (NYSE:DAL) has announcing adding seasonal flight to Tucson from Seattle. The announced flight additions include weekly nonstop flights departing from Seattle and ending at Tucson International Airport. This is part of the company’s expansion of services, a dream that has been lingering around. The new Seattle flight service begins December 20, and involved weekly Saturday flight to and from Tucson. The flight will depart Seattle at 8.15 a.m. and leave the Old Pueblo at 12.40 p.m. DAL has also included five daily nonstop Seattle flights to Phoenix, a Saturday seasonal flight to Jackson Hole and daily seasonal service to Palm Springs among others. This way, Delta Air Lines, Inc. (NYSE:DAL) is sitting well to take on the rival Alaska Airlines.
Bristol-Myers Squibb Co (NYSE:BMY) gained significantly Monday after the stock earned a rating boost, thanks to its promising cancer drugs. The stock was upgraded by BMO Capital Markets analyst from “market-perform” to “outperform.” The price target on BMY was also hoisted at $60, up from $56 in the previous sentiment. Bristol-Myers Squibb Co (NYSE:BMY) is working on a group of cancer drug that uses the immune system to combat cancer and this approach is very promising. Still, the company has recently entered in partnerships for development of effective cancer therapies and all these suggest its bright future.
